Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8IUF8

UPID:
RIOX2_HUMAN

ALTERNATIVE NAMES:
60S ribosomal protein L27a histidine hydroxylase; Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA; Histone lysine demethylase MINA; MYC-induced nuclear antigen; Mineral dust-induced gene protein; Nucleolar protein 52; Ribosomal oxygenase MINA

ALTERNATIVE UPACC:
Q8IUF8; D3DN35; Q6AHW4; Q6SKS0; Q8IU69; Q8IUF6; Q8IUF7; Q96C17; Q96KB0

BACKGROUND:
Ribosomal oxygenase 2, also recognized under names such as MYC-induced nuclear antigen and Mineral dust-induced gene protein, is integral to cell physiology. It functions both as a histone lysine demethylase and a ribosomal histidine hydroxylase, involved in key processes like the demethylation of H3K9me3 and hydroxylation of ribosomal protein L27a. Its role is essential in ensuring efficient ribosome biogenesis and cell survival.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Ribosomal oxygenase 2 holds promise for unveiling new therapeutic avenues. Its involvement in critical cellular processes underscores its potential as a target for innovative treatment strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.